Spectral AI, Inc.

DeepView Diagnostics is an AI company specializing in predictive medical diagnostics. Its core product, the DeepView System, utilizes proprietary AI algorithms to identify fully damaged, partially damaged, and healthy human tissue characteristics that are not visible to the naked eye at the initial presentation of a wound. The system provides a binary prediction on whether a wound will heal by a specific future time point, assisting healthcare professionals in making more accurate, timely, and informed treatment decisions. The company's primary focus is on burn indications. The DeepView System, which integrates a multispectral imaging (MSI) component with the predictive AI-Burn® software, received United Kingdom Conformity Assessed (UKCA) marking for use in the United Kingdom for burn indications on February 22, 2024, with the registration fully completed on March 7, 2024. The business plans to have two revenue streams: a Software as a Service (SaaS) model for its software, operating under a Software as a Medical Device (SaMD) regulatory framework, and revenue from its imaging device component. The SaaS component will include a software licensing fee covering maintenance, image hosting, and algorithmic updates. The proprietary imaging device, which acquires images for the AI algorithms, is a universal platform designed to support multiple clinical indications beyond burn wound healing analysis. Pricing for these components will be determined strategically per country and site-of-service. The MSI technology within the DeepView System uses patented multi-spectral optics and sensors to capture injured tissue images across near UV, human visible, and near infrared (NIR) wavelengths.